Despite Advances in ARVs, HTE Patients May Struggle to Maintain Viral Suppression and Have Limited Treatment Options^1,2

Over the past 3 decades, antiretroviral treatment for HIV has improved considerably with the approval of additional classes of treatment. However, there are still people with HIV who struggle to achieve viral suppression due to multiple factors.^1,3

The FDA considers patients to be HTE if they⁴:

Have resistance to multiple drugs and drug classes

Are unable to construct a regimen that suppresses HIV RNA to below assay quantification limits

For HTE patients, the journey to viral suppression is challenging and nonlinear. Clinical and logistical challenges may contribute to treatment failures. In the US alone, a large multicenter study from 2000 to 2017 found that the median number of prior ARVs taken by HTE patients with limited treatment options was 11.^2,3,5,*